BofA analyst Tazeen Ahmad lowered the firm’s price target on Argenx (ARGX) to EUR 680 from EUR 736 and keeps a Buy rating on the shares. The firm updated models in smid-cap biotech as part of a Q1 earnings preview. Argenx remains one of the analyst’s 2025 top picks.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $796 from $681 at Citi
- Argenx Se’s Growth Potential Bolstered by Vyvgart Hytrulo Approval and Strategic Positioning
- Vyvgart for self-administration ‘immaterial’ to Option Care, says JPMorgan
- Argenx Se: FDA Approval and Strategic Developments Drive Buy Rating
- Argenx SE Gains FDA Approval for VYVGART Hytrulo Self-Injection Option